What are the criteria for parathyroidectomy (surgical removal of a parathyroid gland)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Parathyroidectomy is recommended for patients with primary hyperparathyroidism who meet specific criteria, including symptomatic patients, those with serum calcium levels greater than 1 mg/dL above the upper limit of normal, osteoporosis, estimated glomerular filtration rate less than 60 mL/min, or presence of kidney stones. The decision to perform parathyroidectomy is based on the presence of specific clinical criteria, rather than the level of parathyroid hormone (PTH) concentration 1.

Indications for Parathyroidectomy

The following are indications for parathyroidectomy:

  • Symptomatic patients
  • Patients with serum calcium levels greater than 1 mg/dL above the upper limit of normal
  • Patients with osteoporosis (T-score less than -2.5 at any site)
  • Estimated glomerular filtration rate less than 60 mL/min
  • Presence of kidney stones on imaging or history of kidney stones
  • Patients with significant hypercalciuria (>400 mg/day) or those who cannot participate in appropriate follow-up

Preoperative Evaluation

Before surgery, localization studies like sestamibi scanning or ultrasound are typically performed to identify the abnormal gland(s) 1.

Surgical Approach

There are two accepted curative operative strategies for primary hyperparathyroidism: bilateral neck exploration (BNE) and minimally invasive parathyroidectomy (MIP) 1. The choice of procedure depends on the specific clinical circumstances and the expertise of the surgeon.

Postoperative Care

After parathyroidectomy, patients should be monitored for potential complications, including recurrent laryngeal nerve injury, hypoparathyroidism, and bleeding 1.

Monitoring and Follow-up

Asymptomatic patients who do not meet the criteria for parathyroidectomy may be monitored with annual serum calcium measurements and bone density testing every 1-2 years 1.

From the Research

Criteria for Parathyroidectomy

The decision to perform a parathyroidectomy is based on several factors, including the presence of symptoms, the level of hypercalcemia, and the presence of end-organ damage.

  • Patients with primary hyperparathyroidism (PHPT) who have symptoms such as osteoporosis, hypercalciuria, vertebral fractures, and nephrolithiasis are considered candidates for parathyroidectomy 2.
  • Asymptomatic patients with PHPT who are at risk of progression or have subclinical evidence of end-organ sequelae are also considered candidates for parathyroidectomy 2.
  • The criteria for evaluating the outcome of parathyroidectomy include the level of serum calcium and parathyroid hormone (PTH) 3.
  • Patients with a serum calcium level > 10.6 mg/dL and elevated intact PTH (iPTH) levels are considered to have recurrent hyperparathyroidism 3.
  • Factors that are positively associated with parathyroidectomy include nephrolithiasis and non-Hispanic white race/ethnicity, while age, Elixhauser Comorbidity Index score, decreased estimated glomerular filtration rate, and diagnosis of osteoporosis are inversely related to surgery 4.

Medical Treatment

Medical treatment options are available for patients with primary, secondary, and tertiary hyperparathyroidism.

  • Cinacalcet, a calcium sensing receptor agonist, can be used to decrease PTH and calcium levels in patients with primary hyperparathyroidism, secondary hyperparathyroidism caused by uremia, and tertiary hyperparathyroidism 5.
  • Newer analogues of vitamin D, such as paricalcitol, have also been introduced and may have an advantage over traditional compounds such as alphacalcidol and calcitriol 5.
  • Vitamin D receptor activators (VDRAs) are widely used for the treatment of secondary hyperparathyroidism, but have calcemic and phosphatemic effects that limit their use to a subset of patients 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Primary hyperparathyroidism.

Nature reviews. Endocrinology, 2018

Research

Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.